JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Bullous systemic lupus erythematosus induced by UVB: report a case.

Bullous systemic lupus erythematosus (BSLE) is a rare blistering disease that dramatically responds to dapsone administration without leaving any scar. Generally, those patients with BSLE meet the criteria for systemic lupus erythematosus, but some have a widespread vesiculobullous eruption only as an initial manifestation without any specific clinical or laboratory findings that fulfill the American College of Rheumatology diagnostic criteria for SLE. The authors report here a middle-aged female patient, whose diagnosis of BSLE was suspected at first from the characteristic vesiculobullous eruption, histopathology, immunofluorescent pattern, and positive antinuclear antibody, who was later confirmed to have UVB photosensitivity that induced the typical skin lesions.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app